BIOIO, LLC

Saint Louis, MO · Biotech · Private

Novel small-molecule insulin-sensitizing compounds (MSDC-5514 and MSDC-5445) targeting PLD1 signaling for NASH treatment

Grants
$2.9M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Novel insulin-sensitizing NASH/diabetes drugs.$223,817
Federal grantDepartment of Health and Human Services · Phase I · Drug target identification using CRISPRi/a screening$224,455
Federal grantDepartment of Health and Human Services · Phase II · Novel insulin-sensitizing NASH/diabetes drugs.$1,492,578
Federal grantDepartment of Health and Human Services · Phase II · Novel insulin-sensitizing NASH/diabetes drugs.$497,526
Federal grantDepartment of Health and Human Services · Phase II · Novel insulin-sensitizing NASH/diabetes drugs.$497,526
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2534A2 THERAPEUTICS, INC.——
2535Deverra Therapeutics—$2.5M
2536ELIAS Animal Health, LLC—$2.4M
2537BIOIO, LLC——
2538EIKONIZO THERAPEUTICS, INC.—$2.4M
2539Topos Bio, Inc.—$9.0M
2540Addition Therapeutics—$28M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.